Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
Blood Cancer Discov. 2024 Mar 1;5(2):90-94. doi: 10.1158/2643-3230.BCD-23-0228.
Immune-related toxicities including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are common side effects of bispecific antibody and chimeric antigen receptor (CAR) T-cell therapies of hematologic malignancies. As anti-inflammatory therapy (the standard of care) is variably effective in mitigating these toxicities after onset, here we discuss emerging evidence for shifting the strategy from mitigation to prevention.
免疫相关毒性包括细胞因子释放综合征（CRS）和免疫效应细胞相关神经毒性综合征（ICANS），是血液系统恶性肿瘤双特异性抗体和嵌合抗原受体（CAR）T 细胞治疗的常见副作用。由于抗炎治疗（标准护理）在发病后缓解这些毒性的效果各不相同，因此我们在此讨论将策略从缓解转向预防的新证据。
